BioTech
Gilead must be held accountable for the harm caused by ‘patent hopping’ an HIV treatment
Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June to settle a case in federal court for $40 million
Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June to settle a case in federal court for $40 million
Imagine this post-9/11 scenario: A New York City fire company is forced to shut down and lay off its firefighters because some Americans believe a